<VariationArchive VariationID="100728" VariationName="NM_000405.5(GM2A):c.333del (p.Cys112fs)" VariationType="Deletion" Accession="VCV000100728" Version="2" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-06-23" DateCreated="2014-02-27" MostRecentSubmission="2022-05-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="106593" VariationID="100728">
      <GeneList>
        <Gene Symbol="GM2A" FullName="ganglioside GM2 activator" GeneID="2760" HGNC_ID="HGNC:4367" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>5q33.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="151253185" stop="151270440" display_start="151253185" display_stop="151270440" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="150632612" stop="150649954" display_start="150632612" display_stop="150649954" Strand="+" />
          </Location>
          <OMIM>613109</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000405.5(GM2A):c.333del (p.Cys112fs)</Name>
      <CanonicalSPDI>NC_000005.10:151266819:C:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>5q33.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="151266820" stop="151266820" display_start="151266820" display_stop="151266820" variantLength="1" positionVCF="151266819" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="150646381" stop="150646381" display_start="150646381" display_stop="150646381" variantLength="1" positionVCF="150646380" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>C112fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000005.10" sequenceAccession="NC_000005" sequenceVersion="10" change="g.151266820del" Assembly="GRCh38">
            <Expression>NC_000005.10:g.151266820del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000005.9" sequenceAccession="NC_000005" sequenceVersion="9" change="g.150646381del" Assembly="GRCh37">
            <Expression>NC_000005.9:g.150646381del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009059.1" sequenceAccession="NG_009059" sequenceVersion="1" change="g.18769del">
            <Expression>NG_009059.1:g.18769del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000405.5" sequenceAccession="NM_000405" sequenceVersion="5" change="c.333del" MANESelect="true">
            <Expression>NM_000405.5:c.333del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000396.2" sequenceAccession="NP_000396" sequenceVersion="2" change="p.Cys112fs">
            <Expression>NP_000396.2:p.Cys112fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001167607.3" sequenceAccession="NM_001167607" sequenceVersion="3" change="c.333del">
            <Expression>NM_001167607.3:c.333del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001161079.1" sequenceAccession="NP_001161079" sequenceVersion="1" change="p.Cys112fs">
            <Expression>NP_001161079.1:p.Cys112fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA267586" DB="ClinGen" />
        <XRef Type="rs" ID="587779405" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00001" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000405.5(GM2A):c.333del (p.Cys112fs) AND Tay-Sachs disease" Accession="RCV000087094" Version="2">
        <ClassifiedConditionList TraitSetID="1067">
          <ClassifiedCondition DB="MedGen" ID="C0039373">Tay-Sachs disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000405.5(GM2A):c.333del (p.Cys112fs) AND Tay-Sachs disease, variant AB" Accession="RCV002247494" Version="1">
        <ClassifiedConditionList TraitSetID="105">
          <ClassifiedCondition DB="MedGen" ID="C0268275">Tay-Sachs disease, variant AB</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-05-04" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2014-02-27" MostRecentSubmission="2022-05-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="1067" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="6027" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hexosaminidase A Deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM2 gangliosidosis, type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HexA deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hexosaminidase alpha-subunit deficiency (variant B)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sphingolipidosis, Tay-Sachs</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Tay-Sachs disease</ElementValue>
                <XRef ID="Tay+Sachs+disease/7008" DB="Genetic Alliance" />
                <XRef ID="MONDO:0010100" DB="MONDO" />
                <XRef ID="111385000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">TSD</ElementValue>
                <XRef Type="MIM" ID="272800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">HEXA disorders are best considered as a disease continuum based on the amount of residual beta-hexosaminidase A (HEX A) enzyme activity. This, in turn, depends on the molecular characteristics and biological impact of the HEXA pathogenic variants. HEX A is necessary for degradation of GM2 ganglioside; without well-functioning enzymes, GM2 ganglioside builds up in the lysosomes of brain and nerve cells. The classic clinical phenotype is known as Tay-Sachs disease (TSD), characterized by progressive weakness, loss of motor skills beginning between ages three and six months, decreased visual attentiveness, and increased or exaggerated startle response with a cherry-red spot observable on the retina followed by developmental plateau and loss of skills after eight to ten months. Seizures are common by 12 months with further deterioration in the second year of life and death occurring between ages two and three years with some survival to five to seven years. Subacute juvenile TSD is associated with normal developmental milestones until age two years, when the emergence of abnormal gait or dysarthria is noted followed by loss of previously acquired skills and cognitive decline. Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration. Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis. Clinical variability even among affected members of the same family is observed in both the subacute juvenile and the late-onset TSD phenotypes.</Attribute>
                <XRef ID="NBK1218" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7737" />
                <XRef ID="7737" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301397</ID>
                <ID Source="BookShelf">NBK1218</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2011">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Carrier-Screening-ACT-SheetAshkenazi-Jewish-Genetic-Disorders.aspx</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders</CitationText>
              </Citation>
              <XRef ID="845" DB="Orphanet" />
              <XRef ID="C0039373" DB="MedGen" />
              <XRef ID="MONDO:0010100" DB="MONDO" />
              <XRef Type="MIM" ID="272800" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="105" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5205" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gm2-gangliosidosis, ab variant</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Tay-Sachs disease, variant AB</ElementValue>
                <XRef ID="Gm2-gangliosidosis%2C+ab+variant/8491" DB="Genetic Alliance" />
                <XRef ID="71253000" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17406" />
                <XRef ID="17406" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Acute infantile GM2 activator deficiency is a neurodegenerative disorder in which infants, who are generally normal at birth, have progressive weakness and slowing of developmental progress between ages four and 12 months. An ensuing developmental plateau is followed by progressively rapid developmental regression. By the second year of life decerebrate posturing, difficulty in swallowing, and worsening seizures lead to an unresponsive vegetative state. Death usually occurs between ages two and three years.</Attribute>
                <XRef ID="NBK583219" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">36007105</ID>
                <ID Source="BookShelf">NBK583219</ID>
              </Citation>
              <XRef ID="309246" DB="Orphanet" />
              <XRef ID="C0268275" DB="MedGen" />
              <XRef ID="MONDO:0010099" DB="MONDO" />
              <XRef Type="MIM" ID="272750" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4933181" SubmissionDate="2022-05-21" DateLastUpdated="2022-05-28" DateCreated="2022-05-28">
        <ClinVarSubmissionID localKey="NC_000005.10:g.151266820_151266820delC|OMIM:272750" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002516493" DateUpdated="2022-05-28" DateCreated="2022-05-28" Type="SCV" Version="1" SubmitterName="Mendelics" OrgID="500035" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Mendelics Assertion Criteria 2019</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fxi2k7be/mendelics_assertion_criteria_2019.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GM2A" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000005.10:g.151266820_151266820delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="272750" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>MENDELICS_CLINVAR_033</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="211165" SubmissionDate="2014-02-25" DateLastUpdated="2014-02-27" DateCreated="2014-02-27">
        <ClinVarSubmissionID localKey="NM_000405.4:c.333delC|OMIM:272800" />
        <ClinVarAccession Accession="SCV000119951" DateUpdated="2014-02-27" DateCreated="2014-02-27" Type="SCV" Version="1" SubmitterName="Unidad de Diagnostico y Tratamiento de Errores Congenitos del Metabolismo. Hospital Clínico Universitário de Santiago de Compostela" OrgID="504796" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GM2A" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000405: exon 3</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>p. Cys112Valfs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000405.4:c.333delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Tay-Sachs disease</ElementValue>
            </Name>
            <XRef DB="OMIM" ID="272800" Type="MIM" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4933181" TraitType="Disease" MappingType="XRef" MappingValue="272750" MappingRef="OMIM">
        <MedGen CUI="C0268275" Name="Tay-Sachs disease, variant AB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="211165" TraitType="Disease" MappingType="Name" MappingValue="Tay-Sachs disease" MappingRef="Preferred">
        <MedGen CUI="C0039373" Name="Tay-Sachs disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

